429 related articles for article (PubMed ID: 16821793)
21. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
Guise CP; Grove JI; Hyde EI; Searle PF
Gene Ther; 2007 Apr; 14(8):690-8. PubMed ID: 17301844
[TBL] [Abstract][Full Text] [Related]
22. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ
Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484
[TBL] [Abstract][Full Text] [Related]
23. Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapy.
Asche C; Dumy P; Carrez D; Croisy A; Demeunynck M
Bioorg Med Chem Lett; 2006 Apr; 16(7):1990-4. PubMed ID: 16442795
[TBL] [Abstract][Full Text] [Related]
24. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
McNeish IA; Green NK; Gilligan MG; Ford MJ; Mautner V; Young LS; Kerr DJ; Searle PF
Gene Ther; 1998 Aug; 5(8):1061-9. PubMed ID: 10326029
[TBL] [Abstract][Full Text] [Related]
25. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
Singleton DC; Li D; Bai SY; Syddall SP; Smaill JB; Shen Y; Denny WA; Wilson WR; Patterson AV
Cancer Gene Ther; 2007 Dec; 14(12):953-67. PubMed ID: 17975564
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase.
Atwell GJ; Boyd M; Palmer BD; Anderson RF; Pullen SM; Wilson WR; Denny WA
Anticancer Drug Des; 1996 Oct; 11(7):553-67. PubMed ID: 8921936
[TBL] [Abstract][Full Text] [Related]
27. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
Benouchan M; Do Nascimento F; Perret GY; Colombo BM
Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of CB1954 reduction by Escherichia coli nitroreductase.
Christofferson A; Wilkie J
Biochem Soc Trans; 2009 Apr; 37(Pt 2):413-8. PubMed ID: 19290872
[TBL] [Abstract][Full Text] [Related]
29. Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation.
Emptage CD; Knox RJ; Danson MJ; Hough DW
Biochem Pharmacol; 2009 Jan; 77(1):21-9. PubMed ID: 18840409
[TBL] [Abstract][Full Text] [Related]
30. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
Drabek D; Guy J; Craig R; Grosveld F
Gene Ther; 1997 Feb; 4(2):93-100. PubMed ID: 9081711
[TBL] [Abstract][Full Text] [Related]
31. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase.
Anlezark GM; Melton RG; Sherwood RF; Wilson WR; Denny WA; Palmer BD; Knox RJ; Friedlos F; Williams A
Biochem Pharmacol; 1995 Aug; 50(5):609-18. PubMed ID: 7669063
[TBL] [Abstract][Full Text] [Related]
32. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
33. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954.
Race PR; Lovering AL; White SA; Grove JI; Searle PF; Wrighton CW; Hyde EI
J Mol Biol; 2007 Apr; 368(2):481-92. PubMed ID: 17350040
[TBL] [Abstract][Full Text] [Related]
34. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
35. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
37. Ablation of central nervous system progenitor cells in transgenic rats using bacterial nitroreductase system.
Kwak SP; Malberg JE; Howland DS; Cheng KY; Su J; She Y; Fennell M; Ghavami A
J Neurosci Res; 2007 May; 85(6):1183-93. PubMed ID: 17304579
[TBL] [Abstract][Full Text] [Related]
38. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
Westphal EM; Ge J; Catchpole JR; Ford M; Kenney SC
Cancer Gene Ther; 2000 Jan; 7(1):97-106. PubMed ID: 10678362
[TBL] [Abstract][Full Text] [Related]
39. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase.
Friedlos F; Court S; Ford M; Denny WA; Springer C
Gene Ther; 1998 Jan; 5(1):105-12. PubMed ID: 9536271
[TBL] [Abstract][Full Text] [Related]
40. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
Djeha AH; Hulme A; Dexter MT; Mountain A; Young LS; Searle PF; Kerr DJ; Wrighton CJ
Cancer Gene Ther; 2000 May; 7(5):721-31. PubMed ID: 10830719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
